Bio

Titoli di studio

1994 Laurea in Medicina e Chirurgia (110/110 e Lode, Menzione d’onore), Università degli Studi di Milano.

1998 Specializzazione in Ematologia (50/50 e Lode), Università degli Studi di Pavia.


Attività professionale

2015-attualmente

UNIVERSITA’ VITA-SALUTE SAN RAFFAELE

Professore Ordinario di Scienze Tecniche Mediche Applicate, Facoltà di Medicina e Chirurgia.

2014-attualmente

ISTITUTO SCIENTIFICO OSPEDALE SAN RAFFAELE IRCCS, Milano

Vice Direttore della Divisione di Ricerca di Immunologia, Trapianti e Malattie Infettive

2008-attualmente

ISTITUTO SCIENTIFICO OSPEDALE SAN RAFFAELE IRCCS, Milano

Responsabile Unità di Ematologia Sperimentale.

2005/2015

UNIVERSITÀ VITA-SALUTE SAN RAFFAELE

Professore a contratto, titolare c. elettivo “Terapia Cellulare in Ematologia”, Docente del corso di Ematologia, Corso di Laurea in Medicina e Chirurgia; Professore a contratto, Corso di Laurea in Biotecnologie Mediche; Docente della Scuola di Specializzazione in Ematologia, Facoltà di Medicina.

2000-2007

ISTITUTO SCIENTIFICO OSPEDALE SAN RAFFAELE IRCCS, MILANO

Ricercatore Senior dell’Unità di Ematologia Sperimentale.

1998-2000

FRED HUTCHINSON CANCER RESEARCH CENTER, Seattle, WA, Post-doctoral Fellow, Program in Immunology (PD. Greenberg).

1998-2002

ISTITUTO SCIENTIFICO OSPEDALE SAN RAFFAELE IRCCS, MILANO

Dirigente Medico Unità Clinica di Ematologia e Trapianti di Midollo Osseo.

1996/1998

ISTITUTO SCIENTIFICO OSPEDALE SAN RAFFAELE IRCCS, MILANO

Post-doctoral Fellow-Telethon Institute for Gene Therapy

1993

MEMORIAL SLOAN KETTERING CANCER CENTER, New York

Studente Interno, Bone Marrow Transplant Unit (R. O’Reilly).

 

Altre attività:

Co-PI del trial clinico “Trasferimento del gene suicida HSV-tk in linfociti di donatore per la modulazione in vivo dell’immunità anti-tumorale dopo trapianto di midollo allogenico”. (1994-1998).

PI del trial clinico multicentrico “TK007 A phase I-II study: Infusion of donor lymphocytes that have been engineered with the suicide gene HSV-tk after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with hematological malignancies”. (2001-2007)

Co-PI del trial clinico multicentrico randomizzato “TK008 randomized phase III trial of haplo-HCT followed by add-back strategy of HSV-TK donor lymphocytes versus haploidentical HCT followed by any T cell repletion strategy for high-risk acute leukemia” (2008-attualmente)

Co-PI del trial clinico di fase I-Il: “Cell Therapy of Duchenne Muscular Dystrophy By Intra-Arterial Delivery of HLA-Identical Allogeneic Mesoangioblasts”, San Raffaele, Milano. (2010-2016)

 

 Attività editoriale

Membro del comitato editoriale Molecular Therapy, Molecular Therapy: Methods and Clinical Development (2013-attualmente); Editore Associato di “Human Gene Therapy Clinical Development Gene Therapy Committee” (2012-2014); Editore Associato di “Human Gene Therapy Methods” (2012-2014); Guest Editor, “The Journal of Gene Medicine” , Review Series on “Cancer Gene Therapy”

(2012); Editore Associato di “Human Gene Therapy “(2011-2014); Editore Associato di “The Journal of Gene Medicine” (IF:2.483) (2009-2015); Membro del comitato editoriale di “Frontiers in Alloimmunity and Transplantation” (2011-attualmente); Membro del comitato editoriale Molecular Therapy, Molecular Therapy: Methods and Clinical Development (2013-attualmente); Guest Editor, Human Gene Therapy (IF:4.218), Review Series on “Cancer Gene Therapy (2009); Membro del comitato editoriale Molecular Therapy (2011-2014).

Revisore scientifico per: Nature Medicine, Nature Biotechnology, Nature Comunications, Science Translational Medicine, Blood, Journal of Clinical Investigation, Cancer Research, Human Gene Therapy, The Journal of Gene Medicine, Bone Marrow Transplantation, Human Immunology, Molecular Therapy, Cytotherapy, Experimental Hematology, Hematologica, Hematological Oncology, Journal of Immunology.

Revisore di grant applications per: European research Council (ERC), INSERM (FR), French National Cancer Institute (INCA, FR), The Netherland organization for Health Research and Development (ZonMw-NL) Cancer Research (UK) Innovation and Technology Fund (China),AICR (UK) Leukemia Research (UK), MIUR (IT), Association Francaise contre le Myopathies (AFM, FR), Research Promotion Foundation (Cyprus), IHU-Strarsbourg, Leukemia, Lymphoma Research (UK), Foundation against Cancer (Belgium), Fundació la Marató de TV3 (Spain), Fondation contre le cancer (Belgium), Dutch cancer Society (NL) , Agencie Nationale del la Recherche (FR).

Member of Expert Review Panels, French National Cancer Institute (INCA), Paris (2010-currently)

Partecipazione ad associazioni professionali

Membro di “ASH Awards Committee”, American Society of Hematology (2018-2021); Presidente di “1st EBMT-CTIWP Scientific Symposium: For transplantation to Gene Therapy: the cellular Therapy Evolution”. European Group for Blood and Marrow Transplantation (EBMT)- Cell Therapy and Immunobiology Working Party (CTIWP) (11-13 Nov, 2015); Membro di “Strategic Research Committee”, European Hematology Association (EHA) (2015-attualmente); Membro del Direttivo, European School of Hematology (ESH) (2014-attualmente); Chair di Cell Therapy and Immunobiology Working Party (CTIWP) di EBMT (2014-attualmente); Membro di un pannello di esperti, French National Cancer Institute (INCA), Paris (2010-2012); Chair del Cancer Committee, American Society of Gene and Cell Therapy (ASGCT ) (2012-2014); Membro del Direttivo di ASGCT (2011-2014); Membro del Comitato Scientifico Presidenziale del XVIII Congresso Annuale, European Society of Gene and Cell Therapy (ESGCT),  Milano,  22-25  Ottobre (2010); Membro del Cancer Gene Therapy Committees, ASGCT e di ESGCT (2009-attualmente); Membro del Direttivo, European Society of Gene and Cell Therapy (ESGCT) (2005-2011).

 

Riconoscimenti:

Cancer Research Institute Fellowship, NY, USA (1999-2001); Young Investigator Award. American Society of Gene Therapy(2005); Young Investigator Award. Fondazione Berlucchi (2006); Grant MIUR-IDEAS, for top 8% ranked by the European Research Council (ERC) (2009);  Team Science Recognition Award (iSBTC, now SITC) (2010); Van Bekkum Award. European Society of Bone Marrow Transplantation (EBMT) (2012); Van Rood Award. European Federation of Immunogenetics (EFI)(2012); Jon Van Rood Award. Immunobiology Working Party EBMT (2013); Basic Science Award, EBMT (2014); Melvin Jones Fellow for Humanitarian Services, Lions International (2016); Van Bekkum Award (EBMT) (2016); Basic Science Award (EBMT) (2017).


Competenze:

Il focus del laboratorio è lo sviluppo e la validazione preclinica e clinica di approcci di immunoterapia dei tumori con linfociti T geneticamente modificati.

Il sistema immunitario ha un gran de potenziale nella cura dei tumori. In particolare, il beneficio clinico del trapianto di cellule staminali allogeniche (allo-trapianto), nei confronti di neoplasie ematologiche, è in gran parte dovuto all’azione del sistema immunitario e in particolare dei linfociti T. L’ingegnerizzazione genetica dei linfociti T consente da un lato di aumentarne il profilo di sicurezza e dall’altro l’efficacia.

Abbiamo sviluppato e validato l’uso di linfociti T di donatore, geneticamente manipolati per esprimere un gene suicida, e infusi dopo allo-trapianto al fine di promuovere la risposta anti-tumorale e anti-virale del trapianto, controllandone la tossicità. Questo progetto, iniziato in OSR negli anni ’90, e sviluppato attraverso studi clinici accademici e in seguito sponsorizzati dall’industria, rappresenta il primo prodotto di terapia cellulare e genica approvato in Europa per patologie oncologiche.

L’esperienza acquisita con questo approccio è attualmente utilizzata per lo sviluppo di nuovi prodotti di terapia cellulare per la cura dei tumori.

Recentemente il laboratorio ha disegnato l’approccio di TCR gene editing, una strategia che attraverso la combinazione di strumenti di editing genetico e vettori virali, consente di sostituire la specificità di linfociti T, ridirezionandoli verso antigeni tumorali.

Un’area del laboratorio si occupa di monitoraggio immunologico di pazienti sottoposti a trapianto, terapia cellulare e genica. In questo contesto abbiamo recentemente osservato come i linfociti T a fenotipo central memory e memory stem abbiano una grande capacità di espandersi e persistere in vivo, e rappresentino dunque interessanti sottotipi cellulari per l’immunoterapia dei tumori.

 

Pubblicazioni più rilevanti degli ultimi dieci anni

 

  1. Kaneko S, Mastaglio S, Bondanza A, Punzoni M, Sanvito F, Aldrighetti A, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A, Nagasawa T, Fleischhauer K, Russo V, Traversari C, Ciceri F, Bordignon C and Bonini C. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009 Jan 29;113(5):1006-15.

 

  1. Ciceri F, Bonini C, (FC, CB, equal contribution), Lupo Stanghellini MT, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, Fleischhauer K, Ponzoni M, Vago L, Rossini S, Santoro A, Todisco A, Apperley J, Olavarria E, Slavin S, Weissinger EM, Ganser A, Stadler M, Yannaki E, Fassas A, Anagnostopoulos A, Bregni M, Gallo Stampino C, Bruzzi P, and Bordignon C. Infusion of suicide gene-engineered donor lymphocytes after family haploidentical hemopoietic transplantation for leukemia: the TK007 phase I/II trial. Lancet Oncol. 2009 May;10(5):489-500. Epub 2009 Apr 1.

Editorial: Immune reconstitution after HLA mismatched haemopoietic stem-cell transplantation.” Ringdén O, Karlsson H, Omazic B. Lancet Oncol. 2009 May;10(5):440.

 

3.Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Lupo-Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009 Jul 30;361(5):478-88.

Editorial: “Genetic Trickery — Escape of Leukemia from Immune Attack” John Barrett, M.D., and Bruce R. Blazar, M.D. N Engl J Med. 2009 Jul 30;361(5):424-25.

 

  1. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine 2012 May;18(5):807-15. doi: 10.1038/nm.2700.

Editorial:“Research Highlights: Zinc-finger nucleases hone tumor cell therapy. Jason Kreisberg Nature Biotechnology 30, 411 (2012) doi:10.1038/nbt.2227 Van Bekkum Award 2012, EBMT

Van Rood Award 2012, EFI

 

  1. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, Lupo-Stanghellini MT, Mavilio F, Mondino A, Bicciato S, Recchia A, Bonini C. IL-7 and IL-15 instruct the generation of human memory stem T cells from naïve precursors. Blood. 2013 Jan 24;121(4):573-84. doi: 10.1182/blood-2012-05-431718.

Editorial: ” Inside Blood: Gattinoni L, Restifo NP. Moving T memory stem cells to the clinic. Blood 2013 121:567”.

 

6.Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells. Nature. 2014 Jun 12;510(7504):235-40. doi: 10.1038/nature13420. Epub 2014 May 28.

 

  1. Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B, Valtolina V, Noviello M, Vago L, Bondanza A, Lunghi F, Marktel S,  Bellio L, Bordignon C, Bicciato S,  Peccatori J,  Ciceri F, and  Bonini C. Generation of human memory stem T cells upon haploidentical T-replete hematopoietic stem cell transplantation. Blood 2015 Apr 30;125(18):2865-74. Mar 3. pii: blood-2014-11-608539. [Epub ahead of print]

 

  1. Oliveira G, Ruggiero E, Lupo Stanghellini MT, N. Cieri N, D’Agostino M, Fronza R, Lulay C,  Dionisio F,  Mastaglio S,  Greco R, Peccatori J,  Aiuti A, Ambrosi A,  Biasco L,  Bondanza A, Lambiase A, Traversari C,  Vago L,  Von Kalle C, Schmidt M, Bordignon C,  Ciceri F,  Bonini C. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T-cell immunological memory. Sci Transl Med. 2015 Dec 9;7(317):317ra198. doi: 10.1126/scitranslmed.aac8265.

Research Highlights:  Lingering T cells. Nature Reviews Immunology Published online 25 Jan. 2016; doi:10.1038/nri.2016.14

 

  1. Gattinoni L,  Speiser DE, Lichterfeld, M, Bonini C. T memory stem cells in health and disease: new insights and therapeutic opportunities. Nat Med. 2017 Jan 6;23(1):18-27. doi: 10.1038/nm.4241. Review.

 

  1. Mastaglio S, Genovese P, Magnani Z, Ruggiero E, Landoni E, Camisa B, Schiroli G, Provasi E, Lombardo A, Reik A, Cieri N, Rocchi M, Oliveira G, Escobar G, Casucci M, Gentner B, Spinelli A, Mondino A, Bondanza A, Vago L, Ponzoni M, Ciceri F, Holmes M, Naldini L, and Bonini C. NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD. Blood. 2017 Jun 21. pii: blood-2016-08-732636. doi: 10.1182/blood-2016-08-732636. [Epub ahead of print]

 

  1. Nimitha RM , Baumgartner F, Braun L, et al., Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. Nature Medicine In press.

 

  1. Prestipino A, Emhardt AJ, Aumann K, et al., Oncogenic JAK2 causes PD-L1 expression mediating immune-escape in myeloproliferative neoplasms. Science Translational Medicine. In press

 

 

Complessivamente sono autrice di 103 pubblicazioni (H-index Scopus=36) in riviste scientifiche internazionali e di 7 contributi per libri.

Born in Padova (Italy), August 21, 1969. Italian citizen. Married, two children.

Languages spoken: Italian (mother tongue), English (fluently).

Education and Professional Experience

1994:  MD, summa cum laude, University of Milano Medical School, Milan (Italy)

1994-1998: Board in Hematology, summa cum laude, University of Pavia, (Italy)

1998-2000: Post-doctoral training in Immunology, Greenberg’s Lab, Fred Hutchinson Cancer Research Center, Seattle, WA

1991-1994: Undergraduate student, Experimental Hematology, San Raffaele Scientific Institute (OSR), Milano, Italy

1993: Undergraduate student, Bone Marrow Transplantation Unit, MSKCC, New York

1994-1998: PI of the clinical trial ” Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation.”

1995-1997: Medical fellow, Bone Marrow Transplant Unit, OSR Milano, Italy

1996-1998: Post-doctoral fellow, TIGET (Telethon Institute for Gene Therapy), DIBIT, OSR

1998-2000: Post-doctoral fellow, Program in Immunology, FHCRC Seattle.

1998-2004: Hematologist, Bone Marrow Transplant Unit, OSR (leave of absence 1998-2000).

2000-2008: Group Leader, Experimental Hematology Unit, OSR.

2001-2007: PI of the multicentric clinical trial TK007, sponsored by Molmed s.p.a.

2008- currently: Head of the Experimental Hematology Unit, OSR.

2010- currently: Co-PI of the multicentric TK008 randomized phase III clinical trial.

2014- currently: Deputy Director Division of Immunology, Transplantation and Infectious Diseases, OSR

2015- currently: Professor, Università Vita-Salute San Raffaele, School of Medicine, Milan, Italy.

Scientific Service

Elected Member: Member of the Board of the European Society of Gene and Cell Therapy (ESGCT) (2005-2011); Member of Cancer Gene Therapy Committees of the American Society of Gene and Cell Therapy (ASGCT) and of ESGCT (2009-currently); Presidential Scientific Committee XVIII Annual ESGCT Congress Milan, Oct 22-25 (2010); Member of the ASGCT Board of Directors (2011-2014); Chairman of the ASGCT Cancer Committee (2012-2014); Chairman of the Cell Therapy and Immunobiology Working Party (CTIWP) of EBMT (2014-currently); Member of the Board of the European School of Hematology (ESH) (2014-currently); Member of the Strategic Research Committee, European Hematology Association (EHA) (2015-currently); President of the 1st  EBMT-CTIWP Scientific Symposium: For transplantation to Gene Therapy: the cellular Therapy Evolution (11-13 Nov, 2015); Member of ASH Awards Committee (2018-2021). Member of ASH, ASGCT, ESGCT, SIE, SIES, NIBIT, EHA, EBMT

 

Editorial boards: Associate Editor Journal of Gene Medicine (2009-2015).

Member of the Editorial Board of Frontiers in Immunology (2011-currently). Associate Editor, Human Gene Therapy, Human Gene Therapy Methods, Editorial Board Molecular Therapy (2011-2014); Associate Editor, Human Gene Therapy Clinical Development Gene Therapy Committee (2012-2014); Member of the Editorial Board of Molecular Therapy, Molecular Therapy: Methods and Clinical Development (2013-currently).

 

Reviewer for: Nature Medicine, Nature Biotechnology, Nature Communications, Science Translational Medicine, Blood, Journal of Clinical Investigation, Cancer Research, Human Gene Therapy, The Journal of Gene Medicine, Bone Marrow Transplantation, Human Immunology, Molecular Therapy, Cytotherapy, Experimental Hematology, Hematologica, Hematological Oncology, Oncotarget, Journal of Immunology.

 

Grant Reviewer for European research Council (ERC), INSERM (FR), French National Cancer Institute (INCA, FR), The Netherland organization for Health Research and Development (ZonMw-NL) Cancer Research (UK) Innovation and Technology Fund (China),AICR (UK) Leukemia Research (UK), MIUR (IT), Association Francaise contre le Myopathies (AFM, FR), Research Promotion Foundation (Cyprus), IHU-Strarsbourg, Leukemia, Lymphoma Research (UK), Foundation against Cancer (Belgium), Fundació la Marató de TV3 (Spain), Fondation contre le cancer (Belgium), Dutch cancer Society (NL) , Agencie Nationale del la Recherche (FR).

Member of Expert Review Panels, French National Cancer Institute (INCA), Paris (2010-currently)


Teaching activities:

2001-2015 Assistant Professor in Hematology, Università Vita-Salute San Raffaele (Uni-SR), Milano.

2004-2015 Assistant Professor, Faculty of Medicine, “Speciality School of Hematology”, “School of Biotechnology, Uni-SR.

Since 2004     Supervisor and examiner of PhD Students (International PhD Program in Cellular and Molecular Medicine, PhD Open University Program, Università Vita-Salute San Raffaele, Milano and other Universities throughout Europe).

2014-2016:    Member of the Pedagogic Committee, School of Medicine, Uni-SR.

2014-2016:    Member of the Board of the PhD Program in Molecular Medicine, Uni-SR.

Since 2015     Full Professor, Faculty of Medicine, Università Vita-Salute San Raffaele, Milano.

 

Honors: Cancer Research Institute Fellowship, NY, USA (1999-2001). Young Investigator Award. American Society of Gene Therapy (2005). Young Investigator Award. Fondazione Berlucchi (2006). Grant MIUR-IDEAS, for top 8% ranked by the European Research Council(ERC). (2009).Team Science Recognition Award (iSBTC, now SITC) (2010). Van Bekkum Award. European Society of Bone Marrow Transplantation (EBMT) (2012). Van Rood Award. European Federation of Immunogenetics (EFI) (2012). Jon Van Rood Award. Immunobiology Working Party EBMT (2013). Basic Science Award, EBMT (2014). Melvin Jones Fellow for Humanitarian Services, Lions International (2016). Van Bekkum Award. (EBMT) (2016). Basic Science Award (EBMT) (2017).


Scientific Production

103 papers in international scientific journals, 7 contributions to books. Cumulative citation index (SCOPUS) of 6151. Scopus “h” index: 36. Inventor of 6 international patents.

Invited speaker to more than 100 International Meetings, Workshops and Universities.

Most significant publications 2007-2017:

  1. Kaneko S, Mastaglio S, Bondanza A, Punzoni M, Sanvito F, Aldrighetti A, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A, Nagasawa T, Fleischhauer K, Russo V, Traversari C, Ciceri F, Bordignon C and Bonini C. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009 Jan 29;113(5):1006-15.

 

  1. Ciceri F, Bonini C, (FC, CB, equal contribution), Lupo Stanghellini MT, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, Fleischhauer K, Ponzoni M, Vago L, Rossini S, Santoro A, Todisco A, Apperley J, Olavarria E, Slavin S, Weissinger EM, Ganser A, Stadler M, Yannaki E, Fassas A, Anagnostopoulos A, Bregni M, Gallo Stampino C, Bruzzi P, and Bordignon C. Infusion of suicide gene-engineered donor lymphocytes after family haploidentical hemopoietic transplantation for leukemia: the TK007 phase I/II trial. Lancet Oncol. 2009 May;10(5):489-500. Epub 2009 Apr 1.

Editorial: Immune reconstitution after HLA mismatched haemopoietic stem-cell transplantation.” Ringdén O, Karlsson H, Omazic B. Lancet Oncol. 2009 May;10(5):440.

 

3.Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Lupo-Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009 Jul 30;361(5):478-88.

Editorial: “Genetic Trickery — Escape of Leukemia from Immune Attack” John Barrett, M.D., and Bruce R. Blazar, M.D. N Engl J Med. 2009 Jul 30;361(5):424-25.

 

  1. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine 2012 May;18(5):807-15. doi: 10.1038/nm.2700.

Editorial:“Research Highlights: Zinc-finger nucleases hone tumor cell therapy. Jason Kreisberg Nature Biotechnology 30, 411 (2012) doi:10.1038/nbt.2227 Van Bekkum Award 2012, EBMT

Van Rood Award 2012, EFI

 

  1. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, Lupo-Stanghellini MT, Mavilio F, Mondino A, Bicciato S, Recchia A, Bonini C. IL-7 and IL-15 instruct the generation of human memory stem T cells from naïve precursors. Blood. 2013 Jan 24;121(4):573-84. doi: 10.1182/blood-2012-05-431718.

Editorial: ” Inside Blood: Gattinoni L, Restifo NP. Moving T memory stem cells to the clinic. Blood 2013 121:567”.

 

6.Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells. Nature. 2014 Jun 12;510(7504):235-40. doi: 10.1038/nature13420. Epub 2014 May 28.

 

7.N. Cieri, G. Oliveira, R. Greco, M. Forcato, C. Taccioli, B. Cianciotti, V. Valtolina, M. Noviello, L. Vago, A. Bondanza, F. Lunghi, S. Marktel, L. Bellio, C. Bordignon, S. Bicciato, J. Peccatori, F. Ciceri, and C. Bonini. Generation of human memory stem T cells upon haploidentical T-replete hematopoietic stem cell transplantation. Blood 2015 Apr 30;125(18):2865-74. Mar 3. pii: blood-2014-11-608539. [Epub ahead of print]

 

  1. G. Oliveira, E.Ruggiero, M.T. Lupo Stanghellini, N. Cieri, M. D’Agostino, R. Fronza, C. Lulay, F. Dionisio, S. Mastaglio, R. Greco, J.Peccatori, A. Aiuti, A. Ambrosi, L. Biasco, A. Bondanza, A. Lambiase, C. Traversari, L. Vago, C. Von Kalle, M.Schmidt, C. Bordignon, F. Ciceri, C. Bonini. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T-cell immunological memory. Sci Transl Med. 2015 Dec 9;7(317):317ra198. doi: 10.1126/scitranslmed.aac8265.

Research Highlights:  Lingering T cells. Nature Reviews Immunology Published online 25 Jan. 2016; doi:10.1038/nri.2016.14

 

  1. Gattinoni L,  Speiser DE, Lichterfeld, M, Bonini C. T memory stem cells in health and disease: new insights and therapeutic opportunities. Nat Med. 2017 Jan 6;23(1):18-27. doi: 10.1038/nm.4241. Review.

 

  1. Mastaglio S, Genovese P, Magnani Z, Ruggiero E, Landoni E, Camisa B, Schiroli G, Provasi E, Lombardo A, Reik A, Cieri N, Rocchi M, Oliveira G, Escobar G, Casucci M, Gentner B, Spinelli A, Mondino A, Bondanza A, Vago L, Ponzoni P, Ciceri F, Holmes M, Naldini L, and Bonini C. NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD. Blood. 2017 Jun 21. pii: blood-2016-08-732636. doi: 10.1182/blood-2016-08-732636. [Epub ahead of print]

 

  1. Nimitha RM, Baumgartner F, Braun L, et al., Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. Nature Medicine In press.

 

  1. Prestipino A, Emhardt AJ, Aumann K, et al., Oncogenic JAK2 causes PD-L1 expression mediating immune-escape in myeloproliferative neoplasms. Science Translational Medicine. In press

 

 

 

 

 

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.